Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175551 | 0.75 | HTR2A (0.43) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL30386978 | 0.75 | MAOA (0.39) | HTR2ANOTUMHRH1GRIN1GRIN2B | |
| SCHEMBL3167798 | 0.75 | MAOA (0.39) | HTR2ANOTUMHRH1GRIN1GRIN2B | |
| SCHEMBL23505819 | 0.75 | HTR2A (0.34) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL19829938 | 0.75 | HTR2A (0.43) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL25180633 | 0.75 | HTR2A (0.34) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL19829945 | 0.75 | HTR2A (0.43) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL15145778 | 0.75 | HTR2A (0.43) | HTR2ANOTUMHTR2CSLC6A2SLC6A4 | |
| SCHEMBL30387994 | 0.75 | HTR2A (0.34) | HTR2ANOTUMHTR2CHRH1RET | |
| SCHEMBL6448475 | 0.75 | HTR2A (0.43) | HTR2ANOTUMHTR2CSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-106999479-B | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | 米伦纽姆医药公司 | 2021-07-16 | — | — | CN | disclosed |
| US-7718809-B2 | Chromane substituted benzimidazole derivatives as acid pump antagonists | RAQUALIA PHARMA INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090291977-A1 | Chromane Derivatives Useful As Acid Pump Antagonists | RAQUALIA PHARMA INC. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1893197-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | RAQUALIA PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1838309-B1 | CHROMANE DERIVATIVES USEFUL AS ACID PUMP ANTAGONISTS | PFIZER (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1893197-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1838309-A1 | CHROMANE DERIVATIVES USEFUL AS ACID PUMP ANTAGONISTS | Pfizer, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006134460-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006064339-A1 | CHROMANE DERIVATIVES USEFUL AS ACID PUMP ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | HRH2, HRH4, HRH1 | HTR2A 793/4885NOTUM 2551/4885HTR2C 567/4885 |
| US-20090291977-A1 | Chromane Derivatives Useful As Acid Pump Antagonists | HRH2, HRH1, CHRND | HTR2A 798/4885NOTUM 1896/4885HTR2C 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.